Imricor Medical Systems Starts Clinical Trial at Amsterdam Medical Center

MT Newswires Live

Apr 11, 2025

Imricor Medical Systems (ASX:IMR) started the VISABL-VT clinical trial after performing the first-in-human ventricular ablation guided by real-time interventional cardiac magnetic resonance (iCMR) at the Amsterdam University Medical Center, according to a Friday filing with the Australian bourse.

The trial evaluates the safety and effectiveness of radiofrequency ablation of ventricular tachycardia in ischemic cardiomyopathy using the Vision-MR Ablation Catheter 2.0 in the iCMR environment.

The patient was treated for both right-sided and left-sided premature ventricular complexes, the filing said.

Ventricular ablation is a procedure used to treat ventricular tachycardia, a rapid, abnormal heartbeat.

Price (AUD): $1.36, Change: $+0.18, Percent Change: +14.83%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2526521062"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2526521062\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2526521062?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-11 08:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2526521062","market":"fut","top_or_hot":-1,"title":"Imricor Medical Systems Starts Clinical Trial at Amsterdam Medical Center","media":"MT Newswires Live","content":"<html><body><p> Imricor Medical Systems (ASX:IMR) started the VISABL-VT clinical trial after performing the first-in-human ventricular ablation guided by real-time interventional cardiac magnetic resonance (iCMR) at the Amsterdam University Medical Center, according to a Friday filing with the Australian bourse.</p><p>The trial evaluates the safety and effectiveness of radiofrequency ablation of ventricular tachycardia in ischemic cardiomyopathy using the Vision-MR Ablation Catheter 2.0 in the iCMR environment.</p><p>The patient was treated for both right-sided and left-sided premature ventricular complexes, the filing said.</p><p>Ventricular ablation is a procedure used to treat ventricular tachycardia, a rapid, abnormal heartbeat.</p><p>Price (AUD): $1.36, Change: $+0.18, Percent Change: +14.83%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Imricor Medical Systems Starts Clinical Trial at Amsterdam Medical Center</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImricor Medical Systems Starts Clinical Trial at Amsterdam Medical Center\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-11 08:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Imricor Medical Systems (ASX:IMR) started the VISABL-VT clinical trial after performing the first-in-human ventricular ablation guided by real-time interventional cardiac magnetic resonance (iCMR) at the Amsterdam University Medical Center, according to a Friday filing with the Australian bourse.</p><p>The trial evaluates the safety and effectiveness of radiofrequency ablation of ventricular tachycardia in ischemic cardiomyopathy using the Vision-MR Ablation Catheter 2.0 in the iCMR environment.</p><p>The patient was treated for both right-sided and left-sided premature ventricular complexes, the filing said.</p><p>Ventricular ablation is a procedure used to treat ventricular tachycardia, a rapid, abnormal heartbeat.</p><p>Price (AUD): $1.36, Change: $+0.18, Percent Change: +14.83%</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMR.AU","symbol_name":"IMRICOR MEDICAL SYSTEMS-CDI","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2526521062","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2526521062","pubTimestamp":1744330432,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Imricor Medical Systems  started the VISABL-VT clinical trial after performing the first-in-human ventricular ablation guided by real-time interventional cardiac magnetic resonance  at the Amsterdam University Medical Center, according to a Friday filing with the Australian bourse.The trial evaluates the safety and effectiveness of radiofrequency ablation of ventricular tachycardia in ischemic cardiomyopathy using the Vision-MR Ablation Catheter 2.0 in the iCMR environment.The patient was treated for both right-sided and left-sided premature ventricular complexes, the filing said.Ventricular ablation is a procedure used to treat ventricular tachycardia, a rapid, abnormal heartbeat.Price : $1.36, Change: $+0.18, Percent Change: +14.83%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IMR.AU":"IMRICOR MEDICAL SYSTEMS-CDI","BK7007":"医疗保健设备","BK7508":"医药生物股","BK7503":"科技股"},"translate_title":"Imricor Medical Systems在阿姆斯特丹医疗中心开始临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMR.AU":0.9},"content_text":"Imricor Medical Systems (ASX:IMR) started the VISABL-VT clinical trial after performing the first-in-human ventricular ablation guided by real-time interventional cardiac magnetic resonance (iCMR) at the Amsterdam University Medical Center, according to a Friday filing with the Australian bourse.The trial evaluates the safety and effectiveness of radiofrequency ablation of ventricular tachycardia in ischemic cardiomyopathy using the Vision-MR Ablation Catheter 2.0 in the iCMR environment.The patient was treated for both right-sided and left-sided premature ventricular complexes, the filing said.Ventricular ablation is a procedure used to treat ventricular tachycardia, a rapid, abnormal heartbeat.Price (AUD): $1.36, Change: $+0.18, Percent Change: +14.83%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}